Shit happens: Angry on Surf Excel’s Hindu-Muslim amity ad, saffronists target Microsoft Excel!

Bengaluru, May 8: Karnataka Chief Minister BS Yediyurappa has announced a special package for those involved in leather works, especially those who work on the roadside, informed the state's Deputy Chief Minister Govind M Karjol on Friday. 

The special package has been announced for cobblers and leather workers, who work on the roadside. 

The government has provided relief to 11,722 families at a rate of Rs 5,000 per family. These beneficiaries will be directly credited to their bank account through Dr. Babu Jagjivan Ram Leather Industries Development Corporation.

This special package will help livelihoods for skilled workers, said the Deputy Chief Minister. He congratulated the Chief Minister on the declaration of this special package on behalf of the Department of Social Welfare.

Bantwal, Jan 11: Seven people were booked for organising protest without taking permission or intimation, police said on Saturday.

The alleged accused were identified as Nandavar Juma Masjid President Basheer, Khateeb of the Masjid Abdul Majeed Darimi, Gram Panchayath President Mohammed Shareef Nandavar, former President of Masjid Majeed, Arif Nandavar, Mustafa and Abubaker.

They have been booked for allegedly organising protest outside Nandavar Juma Masjid on Jan 10 afternoon without intimation to police or obtaining permission.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.